EA201100268A1 - Вакцина - Google Patents

Вакцина

Info

Publication number
EA201100268A1
EA201100268A1 EA201100268A EA201100268A EA201100268A1 EA 201100268 A1 EA201100268 A1 EA 201100268A1 EA 201100268 A EA201100268 A EA 201100268A EA 201100268 A EA201100268 A EA 201100268A EA 201100268 A1 EA201100268 A1 EA 201100268A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
vaccine
particle
delivery
combined
Prior art date
Application number
EA201100268A
Other languages
English (en)
Inventor
Ральф Леон Биман
Абделатиф Элуахаби
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201100268A1 publication Critical patent/EA201100268A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

В данном изобретении предлагается иммуногенная композиция, содержащая по меньшей мере одну частицу для доставки антигена и по меньшей мере один антиген, где антиген и частицу для доставки антигена соединяют, используя промежуточный линкер.
EA201100268A 2008-08-28 2009-08-26 Вакцина EA201100268A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9258208P 2008-08-28 2008-08-28
US9574708P 2008-10-15 2008-10-15
US16568809P 2009-04-01 2009-04-01
PCT/EP2009/060967 WO2010023216A1 (en) 2008-08-28 2009-08-26 Vaccine

Publications (1)

Publication Number Publication Date
EA201100268A1 true EA201100268A1 (ru) 2011-10-31

Family

ID=41338517

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100268A EA201100268A1 (ru) 2008-08-28 2009-08-26 Вакцина

Country Status (13)

Country Link
US (1) US8846080B2 (ru)
EP (1) EP2328613A1 (ru)
JP (2) JP5769624B2 (ru)
KR (1) KR20110050531A (ru)
CN (1) CN102202689A (ru)
AU (1) AU2009286769A1 (ru)
BR (1) BRPI0916884A2 (ru)
CA (1) CA2734950A1 (ru)
EA (1) EA201100268A1 (ru)
IL (1) IL211233A0 (ru)
MX (1) MX2011002267A (ru)
WO (1) WO2010023216A1 (ru)
ZA (1) ZA201101481B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2351578T (pt) 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
US9308253B2 (en) * 2011-09-19 2016-04-12 The Johns Hopkins University Cancer immunotherapy
PL2750683T3 (pl) * 2011-10-03 2018-10-31 Mx Adjuvac Ab Nanocząsteczki, sposób ich otrzymywania i ich zastosowanie jako nośnik dla związków amfipatycznych cząsteczek hydrofobowych w dziedzinach medycyny włączając leczenie raka i związki powiązane z żywnością
GB201120000D0 (en) * 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
EP2804624B1 (en) 2012-01-19 2018-12-26 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
CA2932122C (en) * 2013-12-03 2022-04-19 Northwestern University Liposomal particles, methods of making same and uses thereof
EP3508198A1 (en) 2014-06-04 2019-07-10 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3166630A4 (en) 2014-07-07 2018-03-28 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
US20170196953A1 (en) 2014-07-07 2017-07-13 Duke University VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME
BR112017018017A2 (pt) 2015-02-26 2018-04-10 Thevax Genetics Vaccine Co Ltd composição de vacina compreendendo uma proteína imunogênica e adjuvantes de combinação para uso na promoção de respostas de células t específicas de antigenos
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
CA3000617C (en) * 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
CN108697779B (zh) 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
CN109562057A (zh) * 2016-05-16 2019-04-02 传染病研究所 聚乙二醇化脂质体和使用方法
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US10058606B2 (en) 2016-09-19 2018-08-28 Thevax Genetics Vaccine Co., Ltd. Hepatitis B therapeutic vaccines
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
BR112019019177B8 (pt) * 2017-03-29 2022-09-13 Shionogi & Co Composição farmacêutica compreendendo derivados de ácido nucleico tendo atividade imunoestimuladora
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
CN111551729B (zh) * 2020-04-27 2021-02-09 浙江正熙生物技术股份有限公司 藻红蛋白免疫荧光探针制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
CN100334228C (zh) * 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
DE602004010376T2 (de) * 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
CA2549173A1 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
JP2008506683A (ja) * 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
GB0427131D0 (en) 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
WO2006066003A2 (en) * 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
PT2351578T (pt) * 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas

Also Published As

Publication number Publication date
EP2328613A1 (en) 2011-06-08
JP5769624B2 (ja) 2015-08-26
ZA201101481B (en) 2012-07-25
JP2015163617A (ja) 2015-09-10
MX2011002267A (es) 2011-03-30
BRPI0916884A2 (pt) 2016-06-14
US8846080B2 (en) 2014-09-30
WO2010023216A1 (en) 2010-03-04
IL211233A0 (en) 2011-04-28
US20110159081A1 (en) 2011-06-30
AU2009286769A1 (en) 2010-03-04
KR20110050531A (ko) 2011-05-13
CN102202689A (zh) 2011-09-28
CA2734950A1 (en) 2010-03-04
JP2012500827A (ja) 2012-01-12

Similar Documents

Publication Publication Date Title
EA201100268A1 (ru) Вакцина
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
CY1119183T1 (el) Πεπτιδια λυσοσωμiκης στοχευσης και χρησεις αυτων
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
EA201170227A1 (ru) Имидазолкарбоксамиды
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
UA103316C2 (ru) Вакцины на базе флавивирусов с дефектной репликацией и векторы для получения вакцин
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
EA201992456A3 (ru) Самостабилизирующиеся линкерные конъюгаты
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
FR2941231B1 (fr) Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
TN2010000213A1 (en) Wise binding antibodies and epitopes
GB201009273D0 (en) Novel vaccine
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
MX2012003058A (es) Vacunas dirigidas a celulas de langerhans.